Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R H Begent

Showing results (11-20 of 166) with videos related to

Pageof 17
Sort By:
British Journal of Haematology|June 1, 1974
The effect of splenectomy on the haematological response to radiotherapy in Hodgkin's diseaseR H Begent, E Wiltshaw
Biochemical Society Transactions|May 1, 1997
Single-chain Fv antibodies for targeting cancer therapyR H Begent, K A Chester
Clinical and Experimental Immunology|December 1, 1984
Circulating immune complexes (CIC), carcinoembryonic antigen (CEA) and CIC containing CEA as markers for colorectal cancerK A Chester, R H Begent
Seminars in Oncology|June 1, 1982
The management of high-risk choriocarcinomaR H Begent, K D Bagshawe
Cancer Treatment Reviews|September 1, 1990
Antibody targeted therapy in cancer: comparison of murine and clinical studiesR H Begent, R B Pedley
Journal of Clinical Pathology|June 1, 1975
Toxoplasma encephalitis complicating Hodgkin's diseaseJ D Whiteside, R H Begent
Journal of Clinical Pathology|July 1, 1977
Hydroxyproline excretion in infantile gastroenteritisR H Begent, H P Lambert
Human Gene Therapy|February 24, 1998
Targeting strategy for gene delivery to carcinoembryonic antigen-producing cancer cells by retrovirus displaying a single-chain variable fragment antibodyH Konishi, T Ochiya, K A Chester, et al.
British Journal of Cancer|March 1, 1980
A serum factor with potential as a tumour marker in malignant lymphomaR H Begent, D F Tucker, J Keen
Clinical Pharmacokinetics|August 1, 1992
Monoclonal antibody administration. Current clinical pharmacokinetic status and future trendsR H Begent, R B Pedley, J Begent
Pageof 17

Showing results (11-20 of 166) with videos related to

Sort By:
Pageof 17
British Journal of Haematology|June 1, 1974
The effect of splenectomy on the haematological response to radiotherapy in Hodgkin's diseaseR H Begent, E Wiltshaw
Biochemical Society Transactions|May 1, 1997
Single-chain Fv antibodies for targeting cancer therapyR H Begent, K A Chester
Clinical and Experimental Immunology|December 1, 1984
Circulating immune complexes (CIC), carcinoembryonic antigen (CEA) and CIC containing CEA as markers for colorectal cancerK A Chester, R H Begent
Seminars in Oncology|June 1, 1982
The management of high-risk choriocarcinomaR H Begent, K D Bagshawe
Cancer Treatment Reviews|September 1, 1990
Antibody targeted therapy in cancer: comparison of murine and clinical studiesR H Begent, R B Pedley
Journal of Clinical Pathology|June 1, 1975
Toxoplasma encephalitis complicating Hodgkin's diseaseJ D Whiteside, R H Begent
Journal of Clinical Pathology|July 1, 1977
Hydroxyproline excretion in infantile gastroenteritisR H Begent, H P Lambert
Human Gene Therapy|February 24, 1998
Targeting strategy for gene delivery to carcinoembryonic antigen-producing cancer cells by retrovirus displaying a single-chain variable fragment antibodyH Konishi, T Ochiya, K A Chester, et al.
British Journal of Cancer|March 1, 1980
A serum factor with potential as a tumour marker in malignant lymphomaR H Begent, D F Tucker, J Keen
Clinical Pharmacokinetics|August 1, 1992
Monoclonal antibody administration. Current clinical pharmacokinetic status and future trendsR H Begent, R B Pedley, J Begent
Pageof 17